MedeliX
Start asking

Metolazone

ATC code C03BA08

Also known as: Metolazon, Métolazone, Metolazona

Key facts
Active substance
Metolazone
Drug class
Diuretic
ATC code
C03BA08
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Metolazone is, per the US prescribing information, a quinazoline diuretic with thiazide-like properties used to treat edema in heart and kidney disease and hypertension.

What it is used for

  • Salt and water retention, including edema accompanying congestive heart failure.
  • Edema accompanying renal diseases, including nephrotic syndrome and diminished renal function.
  • Hypertension, alone or with antihypertensive drugs of a different class.

Dosing

  • Single daily dose; titrate individually by indication and response to the minimal dose that maintains the desired effect.
  • Edema of cardiac failure or renal disease: 5 to 20 mg once daily.
  • Mild to moderate essential hypertension: 2½ to 5 mg once daily; the blood pressure effect may take three or four days to three to six weeks.
  • Metolazone tablets are not interchangeable with more rapidly available formulations (MYKROX); switching requires new titration – see the full text.
  • Use caution in severely impaired renal function (accumulation may occur).

Contraindications

  • Anuria.
  • Hepatic coma or precoma.
  • Known allergy or hypersensitivity to metolazone.

Important warnings

  • Do not interchange: metolazone tablets with slow and incomplete bioavailability are not therapeutically equivalent at the same doses to MYKROX.
  • Rare rapid onset of severe hyponatremia and/or hypokalemia after initial doses; stop immediately if this occurs.
  • Hypokalemia with weakness, cramps and cardiac dysrhythmias; check potassium regularly, especially with digitalis.
  • Use with furosemide can cause unusually large or prolonged losses of fluid and electrolytes.
  • Hyperuricemia or gout, hyperglycemia, azotemia, hypercalcemia, orthostatic hypotension; cross-allergy with sulfonamides and thiazides.

Side effects

  • Usually well tolerated, with mostly mild and transient adverse reactions; no frequencies are given.
  • Cardiovascular: chest pain, orthostatic hypotension, excessive volume depletion, venous thrombosis, palpitations.
  • Nervous system: syncope, dizziness, lightheadedness, fatigue, weakness, headache.
  • Skin and digestive: toxic epidermal necrolysis, Stevens-Johnson syndrome, photosensitivity, hepatitis, pancreatitis, nausea, vomiting.

Interactions

  • Lithium: diuretics should generally not be given together (high risk of lithium toxicity).
  • Furosemide and probably other loop diuretics: unusually large or prolonged fluid and electrolyte losses.
  • Digitalis glycosides: diuretic-induced hypokalemia can lead to serious arrhythmias.
  • Other antihypertensives, alcohol, barbiturates and narcotics add to the hypotensive effect.

Pregnancy and breastfeeding

  • Routine use of diuretics in an otherwise healthy pregnant woman is inappropriate.
  • Metolazone appears in breast milk.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Brand names in 7 more European countries
Denmark
Metolazon Abcur
Finland
Metolazon Abcur
Iceland
Metolazon Abcur
Italy
Zaroxolyn
Norway
Metolazon Abcur
Portugal
Diulo
Sweden
Metolazon Abcur

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Metolazone (Amici Pharma, Inc) – Prescribing Information, 2026-04-01. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cbfa3d5c-cce9-4afa-b064-06f1e1041eac
  2. Wikidata (CC0): ATC C03BA.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.